Ann: Outstanding SubB2M Ovarian Cancer Test Data, page-382

The next big release coming for Bard1 .

Homework Homework

RUO EXO-NET commercialisation BARD1’s first commercial embodiment of the NET Technology, EXO-NETTM, is on track to be launched as a Research Use Only (RUO) product in the second quarter of CY2021. EXO-NET has been specially designed to capture exosomes from body fluids and cell culture for diagnostic and therapeutic purposes. According to Grand Review Research the exosome market is expected to reach US$2.3 billion by 2030 growing at a CAGR of 18%. Positioning EXO-NETTM RUO as a research tool has the potential to embed the technology into the discovery, research and development phases for multiple liquid biopsy and therapeutic applications. This should also generate multiple new publications which will highlight the value EXO-NETTM can deliver in exosome isolation and development of potential exosome-based products. Importantly, this may lead to future licensing agreements for development and commercialisation of exosome-based products incorporating the Molecular Net technology. During the quarter BARD1 has finalised in-house manufacturing procedures and packaging enabling product availability for launch in Q2 CY2021.